Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 19, 2024
Principal Executive Offices: South San Francisco, California
The Company entered into a Material Definitive Agreement on January 19, 2024, establishing an at-the-market equity offering program.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a new capital raising mechanism.
| Metric | Value |
|---|---|
| Maximum Aggregate Gross Proceeds | $350.0 million |
| Sales Agent Commission | Up to 3.0% of gross sales proceeds |
| Underlying Registration Statement | Form S-3 (File No. 333-272936) |
Material Changes
The primary material change is the execution of an Open Market Sales Agreement with Jefferies LLC. This agreement allows the Company to sell shares of its common stock having aggregate gross proceeds of up to $350.0 million through Jefferies as its sales agent. The Company retains sole discretion over the parameters of the sales, including the number of shares, timing, daily limitations, and minimum price thresholds.
Guidance, Outlook, and Risks
- Management Commentary: The filing states that the Company will set the parameters for the sale of shares, including limitations on the number of shares sold in any one trading day and minimum price floors.
- Termination: The Sales Agreement will terminate upon the earlier of the sale of all shares subject to the agreement or termination in accordance with its terms.
- Risks/Contingencies: The filing notes that the offer and sale of shares are subject to securities laws and will not be made in any jurisdiction where such offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of IDEAYA Biosciences common stock (IDYA) to assess potential dilution impact.
- Review the full text of the Open Market Sales Agreement (Exhibit 10.1) for specific minimum price constraints and daily volume limits.
- Confirm the Company's current cash position and burn rate to understand the urgency of accessing the $350.0 million facility.
- Monitor future filings for actual sales activity and the total number of shares issued under this program.